The effectiveness of combined preventive treatment with Ceftiofur, Oxytocin and PGF2α on fertility parameters in cows

The present study is aimed at evaluating the effectiveness of combined preventive treatment with Ceftiofur Hydrochloride (CHR), Oxytocin (OXT) andPGF2α on fertility parameters and puerperal disorder rates in postpartum (pp)dairy cows. A total of 191 Holstein-Friesian cows were divided into fourgroups. The cows in group I (GI; n=37) and II (GII; n=69) were treated on adaily basis with CHR and OXT for five and three days pp, respectively. GroupIII (GIII; n=52) was designed as the PGF2α group, and group IV (GIV; n=33)served as a control group. The animals in GI, GII, and GIII were given aPGF2α analogue on days 15 and 26 pp. Each group was further divided intosubgroups of normal parturition (np) and dystocia (d) when the study resultswere evaluated. It was found that the first service pregnancy rates for the subgroup of dystocia were significantly higher (P&lt;0.05 and P&lt;0.01) in subgroupGII (76.9%) than in GI (30.0%) and GIV (37.5%). Furthermore, the mediantime to first service and the median time to pregnancy were longer for cowsin subgroup GIVd as compared with subgroups GId, GIId, and GIIId(P&lt;0.001; P&lt;0.01). Group II was found to have the lowest endometritis ratesafter treatment of subgroups-d and -np. No statistically significant differencewas found between the groups with regard to cystic ovary rates after treatment (P&gt;0.05). As the treatment with CHR-OXT combined with PGF2α ondays 15 and 26 was associated to improved uterine involution patterns andreproductive performance, our results suggest that administration of this preventive treatment would be useful, especially for cases of dystocia.&nbsp;</p

Treatment of hypersexuality and benign prostatic hypertrophy with delmadinone acetate in intact male dogs

The aim of the present study was to evaluate the effectiveness of delmadinone acetate (DMA) for the treatment of hypersexuality (HS) and benign prostatic hypertrophy (BPH), which are frequently observed in male dogs, for which no surgical treatment has been indicated. The study was performed with 21 intact male dogs that had HS (n= 12) and signs of BPH (n= 9). DMA (Tardak® or Tardastrex®) was administered subcutaneously to each dog at a dose of 3-5 mg/kg and was repeated 15 days later as a second treatment. DMA administration was repeated in some cases until the clinical signs disappeared. The successful recovery rate of HS cases was found to be 50% after a single application and 25% by the second and third applications. The mean" recovery periods" and mean" stable periods" of these 3 consecutive applications were found to be 5.83, 7.66, and 6.00 days, and 16.7, 18.7, and 20.0 months, respectively. With regard to BPH after consecutive applications, treatment success rates, mean recovery periods, and mean stable periods were 33.3%, 22.2%, 44.4%, 12.0, 11.0, 9.5 days, and&gt; 30, 12, and 13.5 months, respectively. DMA is clinically applicable as a therapeutic agent for HS and BPH cases; however, repeated applications were required due to temporary recoveries.</p